The global biopharmaceuticals market accounted for $ 160,440.4 million in 2014, and it is expected to grow with a CAGR of 9.6% during 2015-2020. The monoclonal antibodies market segment dominated the global biopharmaceuticals market in 2014 with about 25.8% share; whereas, among application segment, the oncology segment accounted for the highest share of 27% in the global biopharmaceuticals market in the same year. The global biopharmaceuticals market is growing with a high growth rate, due to increasing geriatric population, increasing R&D investments, increasing prevalence of chronic diseases, and technological advancements in biopharmaceuticals which has helped in curing diseases with no available treatment.
Biopharmaceuticals are in huge demand due to the increasing prevalence of chronic diseases, which is one of the key drivers, fuelling the growth of the global biopharmaceuticals market. Chronic diseases are increasing due to unhealthy lifestyle, poor diet, excess alcohol consumption, and lack of physical activity. The increase in chronic diseases worldwide is leading to the growth in the number of hospitalization cases, which is fuelling the demand for biopharmaceuticals. The monoclonal antibodies market grew with an average annual growth rate of over 9.3% during 2011-2014. The oncology market on the other hand, grew with a CAGR of 10.9% during 2011-2014.
The R&D investments in formulation and development of a drug have increased, due to the growing demand for prevention, treatment, and complete curative options for various diseases. Many pharmaceutical companies are focusing on developing more effective products to treat life-threatening diseases and encourage patients to live healthier lives with reduced disabilities. The increasing healthcare investments around the world, is propelling the increase in R&D investments, which is fuelling the growth of the global biopharmaceuticals market.
The increasing aging population is propelling the growth of the global biopharmaceuticals market, as the pool of elder population is more prone to illness due to low immunity levels, and high recovery time consumption. The elderly people are also susceptible to dermatological disorders, such as dermatitis and cellulitis. Moreover, common eye diseases, including glaucoma and age-related macular degeneration (AMD) are also age-related diseases. These age-related disorders would require more effective biopharmaceuticals for their treatment, thus fuelling the demand of the global biopharmaceuticals market.
The technological advancements in biopharmaceuticals, such as target specific approach with high efficiency, are proving to be advantageous in treating various disorders and chronic diseases. Additionally, biopharmaceuticals have the potential to prevent, treat, and heal the diseases completely, which are otherwise difficult to cure or have no available treatment.
The restraints associated with the global biopharmaceuticals market include high cost of biopharmaceuticals and side effects, such as breathing problems, sore throat, allergic reactions, itching, and rashes due to the consumption of biopharmaceuticals. The low-cost biosimilars are posing a threat to the global biopharmaceuticals market. Biosimilar refers to a biological product that is approved by drug related authorities, such as the Food Drug Association (FDA) and is similar in function, safety, and effectiveness; just like the original product manufactured by a different company. Furthermore, the easy availability of low-priced biosimilars of existing biopharmaceuticals is hampering the growth of the global biopharmaceuticals market.
The key companies operating in the global biopharmaceuticals market include AbbVie Inc, Eli Lilly and Company, Sanofi, Pfizer Inc., Abbott Laboratories, AstraZeneca PLC, Novartis AG, Biogen Idec , Bristol-Myers Squibb Company, and Amgen Inc.
Provides comprehensive understanding of the market with the help of informed market outlook, opportunities, challenges, trends, size and growth, competitive analysis, major competitors and Porter analysis Identifies the key drivers of growth and challenges of the key industry players. Also, assesses the future impact of the propellants and restraints on the market Uncovers potential demands in the market Porter analysis identifies competitive forces within the market Provides information on the historical and current market size and the future potential of the market Provides sizes of key regional markets using yardsticks of processes, segments, products, end user and technology, etc (as applicable) Highlights the competitive scenario of the market, major competitors, market share, benchmarking, investments and merger acquisitions Provides profiles of major competitors of the market including details of their operations, product and services, recent developments and key financial metrics. Profiles provide better understanding of competition as well as the demands of the market.
Our reports have been used by over 10K customers, including:
The Global Precision Medicine Partnering Terms and Agreements 2014-2021 report provides comprehensive understanding and unprecedented access to the Precision Medicine partnering deals and agreements entered into by the worlds leading healthcare companies. This report provides details of the latest Precision Medicine...
Interferon Alpha/Beta Receptor 2 (Interferon Alpha Binding Protein or Type I Interferon Receptor 2 or IFNAR2) - Drugs in Development, 2021 Summary Interferon Alpha/Beta Receptor 2 (Interferon Alpha Binding Protein or Type I Interferon Receptor 2 or IFNAR2) - Drugs in Development, 2021 provides in...
“Neutropenia - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 30+ pipeline drugs in Neutropenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and...
243 pages •
By Asia Market Information & Development Company
• Apr 2021
China’s demand for Biologics has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption...
162 pages •
By Global Industry Analysts
• Apr 2021
- Global Stem Cells Market to Reach $15.1 Billion by 2027
- Amid the COVID-19 crisis, the global market for Stem Cells estimated at US$9.1 Billion in the year 2020, is projected to reach a revised size of US$15.1 Billion by 2027, growing at aCAGR of 7.4% over the period 2020-2027. Adult Stem Cells, one of...
The microcarriers market is projected to reach USD 2.9 billion by 2026 from USD 1.7 billion in 2021, at a CAGR of 10.7% during the forecast period. Increasing use of single-use bioreactors for bioprocessing, rising investmnet in R&D for developemnt of vaccines and therapeutic protiens, and increasing government funding for cell and gene therapy. •...
Global Academic and Non-Profit Partnering Terms and Agreements 2015 to 2021 report provides a detailed understanding and analysis of how and why companies enter Academic and Non-Profit partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes. This...
175 pages •
By The Business Research Company
• Apr 2021
Major players in the oral biologics and biosimilar market are Novartis, Rani Therapeutics, Eli Lilly and Co., AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, BiosanaPharma, Entera Bio Ltd. and Allergan plc. The global oral biologics & biosimilar drugs market is expected to grow from $3.53 billion in 2020 to...
The Formulation Development Outsourcing market was valued at approximately USD 8,055 million in 2020 and is expected to witness a revenue of USD 12,650 million in 2026, with a CAGR of 7.2% over the forecast period. The rapidly evolving threat of COVID-19 is impacting lives, communities, businesses, and industries around the world. The...
The global cell dissociation market size is projected to reach USD 561 million by 2026 from USD 282 million in 2021, at a CAGR of 14.7% during the forecast period. The growth in this market is attributed to the prevalence of cell based research, the increasing number of pharmaceutical and biotechnology companies. Moreover, the growth opportunities...
Chronic Disease Prevalence
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.